AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01965509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168 or placebo
Description: injection has to administered subcutaneously weekly
Study NCT01965509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEX168 or placebo
Description: injection has to administered subcutaneously weekly
Study NCT00702598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based Cognitive Behaviour Therapy (CBT)
Description: Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
Study NCT00702598 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Telephone reminder calls
Description: Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
Study NCT02536495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT02536495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02536495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02536495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study NCT03993561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment summary and survivorship care plan
Description: Individually tailored counselling session will be implemented within 1 month of treatment completion.
Study NCT02972242 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Field of View
Description: Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography
Study NCT02972242 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Field of View
Description: Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography
Study NCT02003690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Dialectical Behavior Therapy
Study NCT01894971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube
Study NCT02003690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Psychotherapy
Description: Standard of Care Psychotherapy
Study NCT02003690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: Standard of Care Pharmacotherapy
Study NCT02003690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy
Description: Standard of Care Pharmacotherapy
Study NCT00174798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR240600C
Description: once daily
Study NCT00174798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT00174798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: once daily
Study NCT03647202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment A
Description: Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions
Study NCT03647202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment B
Description: Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
Study NCT04865991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCI Propofol
Description: Peripheral venous catheters were placed in all subjects. Subjects in the TCI propofol group had one specific intravenous catheter for propofol infusion apart from medication or intravenous fluid line. Subjects in the TCI Propofol group received TCI propofol (Schneider) with targeted Ce 4 -5 mcg/ml for anesthesia induction and maintenance. Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
Study NCT04865991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: subjects in the sevoflurane group were cannulated only with one venous catheter. Midazolam 0.05 mg/kg BW and fentanyl 1 mcg/kg BW were given as premedication. Subjects in the sevoflurane group received intravenous propofol 1 - 2 mg/kg BW.
Study NCT02227368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
Study NCT02227368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
Study NCT01981070 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Intervention for Parents
Description: See Study Arms
Study NCT01981070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support and Information for Parents
Description: See Study Arms
Study NCT02578459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrathecal Drug Delivery System
Description: The Prometra Pump is a battery-operated, implantable, programmable infusion pump that dispenses pain medication into the intrathecal space through an implanted infusion catheter.
Study NCT02578459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management
Description: Treatment with conventional medical management will include using standard systemic pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and neuropathic medications (examples: gabapentin, Lyrica, Cymbalta) that are typically used to treat pancreatic cancer pain.
Study NCT03189069 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Treatment for NVAF patients
Study NCT03189069 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Description: Treatment for NVAF patients
Study NCT03189069 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Treatment for NVAF patients
Study NCT03189069 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Treatment for NVAF patients
Study NCT01197014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Losartan
Description: Amlodipine/Losartan high dose
Study NCT01197014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Losartan
Description: Amlodipine, Losartan
Study NCT00534105 — intervention group
Intervention type: OTHER
Intervention: Total Cholesterol
Study NCT00534105 — intervention group
Intervention type: OTHER
Intervention: Triglyceride
Study NCT00534105 — intervention group
Intervention type: OTHER
Intervention: HDL
Study NCT00534105 — intervention group
Intervention type: OTHER
Intervention: LDL
Study NCT03827551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delivery of oral hygiene advices
Description: Patients will benefit from hygiene advice and maintenance of good oral health. No treatment will be administered as part of this study. Patients will continue their usual treatment according to the contraindications. Patients will benefit from salivary sampling and a collection of oral bacteria contained in the dental plaque using paper tips. These reviews will be conducted during the Inclusion Visit and the 6 month Follow-Up Visit.
Study NCT02532452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral Specific VST Infusion
Description: VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR >1,000~* Plasma JC Virus PCR > 1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy~* Evidence of PML or other CNS infection due to JC virus
Study NCT01196936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: 5 mg PO Daily
Study NCT01196936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily
Study NCT01196936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital mammography
Description: Correlative studies
Study NCT01196936 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Digital mammography
Description: Correlative studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative Studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative Studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative Studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative Studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative Studies
Study NCT01196936 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: correlative studies
Study NCT01196936 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: protein expression analysis
Description: correlative studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: correlative studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacogenomic studies
Description: correlative studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01196936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration
Study NCT01196936 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fine needle aspiration
Study NCT03647202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment C
Description: Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.
Study NCT02282423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-study dietary and exercise instruction.
Description: All subjects will be instructed to continue their normal diet during the three days prior to study, to not consume alcohol the day before study, and to not engage in exercise for 48 hours before all studies.
Study NCT02282423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening examination and oral glucose tolerance test
Description: All subjects will have screening exam and OGTT at the Clinical Studies Infusion Unit at Mayo Clinic in Arizona at 7-8 am after having eaten nothing after 10 PM the night before, and have a screening examination and 75 g OGTT, as described
Study NCT02282423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp
Description: On a separate day, subjects will have a two-hour euglycemic clamp ((80 mU insulin/(m2.min)) at the Clinical Studies Unit at Mayo Clinic Arizona at 7-8 am after an overnight fast. A muscle biopsy will be taken before the insulin infusion, to serve as the resting biopsy (3). Biopsy specimens (150-300 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed
Study NCT02282423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VO2max.
Description: VO2max.
Study NCT02282423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute exercise bout
Description: The single acute exercise bout will be performed as described (3). It consists of 4 sets of 12 min each (8 min @ 70% VO2max, 2 min @ 90%, 2 min rest, repeat X 4). Biopsies are taken 30 min and 24 hr after end of exercise. Resting biopsies are taken on the glucose clamp day
Study NCT02282423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous needle muscle biopsies
Description: Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing. We routinely obtain 150-300 mg muscle (wet weight), which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein, as described (2, 3, 12).
Study NCT01068405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
Study NCT01068405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
Study NCT01145820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice plus
Description: Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
Study NCT01145820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Juice plus
Description: Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
Study NCT00951171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine Insemination
Description: The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
Study NCT00951171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI with the standard inseminator
Description: The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
Study NCT04429646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous left atrial appendage closure-LAMax
Description: Interventional device, LAMax left atrial appendage closure system
Study NCT04429646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous left atrial appendage closure-Watchman
Description: Interventional device, Watchman® LAA Closure Device
Study NCT00371462 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use of PDA + support to reduce weight and pain
Description: participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
Study NCT00371462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE! level 2 group weight loss counseling
Description: Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
Study NCT02542410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Study NCT02542410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone acetate
Study NCT01709396 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ED-TBI
Description: Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
Study NCT00940654 — intervention group
Intervention type: OTHER
Intervention: Antipyretic therapy
Description: External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
Study NCT00835510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine cream 1% manufactured by Taro
Description: Treatment applied to affected area twice daily for 7 days
Study NCT00835510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrimin Ultra (butenafine) 1%
Description: Treatment applied to affected area twice daily for 7 days
Study NCT00835510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Butenafine Vehicle manufactured by Taro
Description: Treatment applied to affected area twice daily for 7 days
Study NCT02895243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
Study NCT04069533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L102
Description: CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
Study NCT00103532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Choices - Motivational Enhancement Intervention
Description: Participants who are randomized to the intervention group will participate in four sessions (over approximately 3 months) of Healthy Choices; a motivational enhancement intervention specifically designed to target multiple risk behaviors in HIV+ youth. Participants will receive individualized referrals at the fourth session.
Study NCT00103532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive standard care plus referrals at three months post-baseline
Study NCT00861796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary Studies
Study NCT01196936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary Studies
Study NCT00520767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
Study NCT00520767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
Study NCT00520767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Melphalan 9 mg/m2/day days 1-4
Study NCT01014221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: acupuncture administered in 8 sessions over 4 weeks
Study NCT01014221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
Study NCT01758861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO group
Study NCT01758861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02398058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
Study NCT02398058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: olaparib will be administered in a continuous daily dose every 12 hours
Study NCT03197103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Description: For more information read Experimental Arm description
Study NCT02165904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult Autologous Mesenchymal Bone Marrow Cell
Description: Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.